Coherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC Wainwright

Coherus BioSciences (NASDAQ:CHRS - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $7.00 price objective on the biotechnology company's stock.

Other research analysts have also issued reports about the company. UBS Group reaffirmed a "neutral" rating and issued a $1.05 target price (down from $1.50) on shares of Coherus BioSciences in a research report on Thursday. StockNews.com cut Coherus BioSciences from a "hold" rating to a "sell" rating in a research note on Tuesday, April 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $5.26.

Coherus BioSciences Price Performance

Coherus BioSciences stock opened at $1.03 on Tuesday. Coherus BioSciences has a 12 month low of $0.66 and a 12 month high of $2.43. The stock has a market cap of $119.37 million, a P/E ratio of -12.88 and a beta of 1.01. The company's fifty day simple moving average is $0.97 and its 200-day simple moving average is $1.12.

Institutional Trading of Coherus BioSciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. bought a new position in shares of Coherus BioSciences in the 4th quarter valued at approximately $7,291,000. Tang Capital Management LLC lifted its stake in shares of Coherus BioSciences by 55.3% in the fourth quarter. Tang Capital Management LLC now owns 3,650,000 shares of the biotechnology company's stock worth $5,037,000 after buying an additional 1,300,000 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Coherus BioSciences by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 2,599,639 shares of the biotechnology company's stock worth $3,588,000 after buying an additional 34,494 shares during the period. CM Management LLC grew its stake in Coherus BioSciences by 2.5% in the 4th quarter. CM Management LLC now owns 2,050,000 shares of the biotechnology company's stock valued at $2,829,000 after buying an additional 50,000 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its stake in Coherus BioSciences by 20.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 1,116,142 shares of the biotechnology company's stock valued at $1,540,000 after buying an additional 186,010 shares during the last quarter. Institutional investors and hedge funds own 72.82% of the company's stock.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.